Stockscreener 앱 받기
4.5969
0.97%
0.0469
전일 마감가:
$4.55
열려 있는:
$4.55
하루 거래량:
751.86K
Relative Volume:
0.55
시가총액:
$388.18M
수익:
$20.65M
순이익/손실:
$-192.65M
주가수익비율:
-1.4501
EPS:
-3.17
순현금흐름:
$-134.39M
1주 성능:
-14.61%
1개월 성능:
-17.22%
6개월 성능:
-17.07%
1년 성능:
-59.84%
1일 변동 폭
$4.44
$4.69
1주일 범위
$4.44
$5.44
52주 변동 폭
$4.305
$19.34
Verve Therapeutics Inc Stock (VERV) Company Profile
명칭
Verve Therapeutics Inc
전화
(978) 501-3026
주소
201 BROOKLINE AVENUE, BOSTON
VERV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| VERV | 4.595 | 388.18M | 20.65M | -192.65M | -134.39M | -3.17 |
| VRTX | 450.67 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.51 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.00 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-10-06 | 개시 | Credit Suisse | Neutral |
| 2022-08-25 | 업그레이드 | Stifel | Hold → Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-07-12 | 개시 | Guggenheim | Buy |
| 2021-07-12 | 개시 | JP Morgan | Neutral |
| 2021-07-12 | 개시 | Jefferies | Buy |
| 2021-07-12 | 개시 | William Blair | Outperform |
모두보기
Verve Therapeutics Inc 주식(VERV)의 최신 뉴스
FY2024 EPS Forecast for Verve Therapeutics Raised by Analyst - MarketBeat
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles - Investing.com India
Verve Therapeutics' SWOT analysis: gene editing firm's stock faces hurdles By Investing.com - Investing.com UK
(VERV) On The My Stocks Page - Stock Traders Daily
What is William Blair's Forecast for VERV FY2024 Earnings? - MarketBeat
FY2024 Earnings Forecast for VERV Issued By Lifesci Capital - MarketBeat
HC Wainwright Cuts Earnings Estimates for Verve Therapeutics - MarketBeat
Analyst Scoreboard: 4 Ratings For Verve Therapeutics - Benzinga
Verve Therapeutics (NASDAQ:VERV) Price Target Lowered to $14.00 at HC Wainwright - MarketBeat
Verve Therapeutics price target raised to $32 from $29 at Canaccord - TipRanks
Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
VERVE Therapeutics stock target cut, keeps buy on trial updates By Investing.com - Investing.com UK
Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright - TipRanks
Verve Therapeutics Reports Q3 Progress and Financials - TipRanks
Verve Therapeutics (VERV) Reports Q3 Loss, Tops Revenue Estimates - MSN
Verve Therapeutics earnings beat by $0.09, revenue topped estimates - Investing.com Canada
Verve Therapeutics (NASDAQ:VERV) Trading Up 10.1%Here's What Happened - MarketBeat
Verve Therapeutics reports Q3 EPS (59c), consensus (70c) - TipRanks
Verve Therapeutics: Q3 Earnings Snapshot - Marketscreener.com
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Vanguard Group Inc's Strategic Reduction in Verve Therapeutics I - GuruFocus.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
VERV Deadline: VERV Investors Have Opportunity to Lead Verve The - GuruFocus.com
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. - GuruFocus.com
Deadline coming up on Oct. 28th in Lawsuit for Investors who lost - openPR
Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - AccessWire
VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AccessWire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - PR Newswire
FINAL VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Verve Therapeutics, Inc. Investors to Join the Class Action Lawsuit! - AccessWire
Verve Therapeutics, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before October 28, 2024 to Discuss Your RightsVERV - cnhinews.com
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, - GlobeNewswire
VERV DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - ForexTV.com
FINAL REMINDER VERV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Verve Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit! - AccessWire
VERV Deadline: Rosen Law Firm Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - Business Wire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - cnhinews.com
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - PR Newswire
VERV DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, - GlobeNewswire
SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 7%Still a Buy? - MarketBeat
Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion - ForexTV.com
Verve Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Verve Therapeutics stock plunges as cholesterol-lowering gene-editing treatment faces setback - MSN
Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights – VERV - ForexTV.com
Verve Therapeutics Inc Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVERV - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - AccessWire
Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - AccessWire
VERV FINAL DEADLINE: RLF, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. - The Bakersfield Californian
VERV FINAL DEADLINE: RLF, RECOGNIZED INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action Commenced by the Firm – VERV - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Investors in Verve Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - AccessWire
Investors who Lost Money on Verve Therapeutics, Inc. (VERV) Should Contact Levi & Korsinsky About Pending Class ActionVERV - AccessWire
Verve Therapeutics Inc (VERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Verve Therapeutics Inc 주식 (VERV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ashe Andrew D. | See Remarks |
May 14 '24 |
Buy |
6.26 |
76,000 |
475,760 |
342,509 |
| Nickerson Joan | Chief Administrative Officer |
Apr 02 '24 |
Sale |
8.24 |
1,514 |
12,475 |
8,659 |
| Dorval Allison | Chief Financial Officer |
Nov 29 '23 |
Sale |
11.45 |
554 |
6,343 |
4,060 |
1.80%
0.42%
자본화:
|
볼륨(24시간):